Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy
NCT ID: NCT02215525
Last Updated: 2014-08-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE3
Total Enrollment
160 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-04-30
Study Completion Date
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A Randomized, Open-Label, Study to evaluate and compare the efficacy and safety, of extracorporeal irradiation of circulating blood by UVA with antioxidant as a supplement (Selenium containing food supplement herbal tablets) in the treatment of non-cirrhotic subjects with chronic hepatitis C.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C
NCT01292161
Hepatitis C
COMPLETED
PHASE2
Hepatitis C Self-Management
NCT00328042
Hepatitis C
Chronic Disease
COMPLETED
NA
Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)
NCT00564811
Hepatitis C
Nutritional Status
Hepatitis, Viral, Human
COMPLETED
NA
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C
NCT03402165
Hepatitis C
UNKNOWN
PHASE4
Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C
NCT01018615
Chronic Hepatitis C
Oxidative Stress
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives: To evaluate and compare the Efficacy and Safety, of extra-corporeal irradiation of circulating blood by extra-corporeal electro-magnetic irradiation with Selenium containing food supplement herbal tablets in the treatment of non-cirrhotic subjects with chronic hepatitis C.
Background and Rationale: As many as 150 million persons are chronically infected with the hepatitis C virus (HCV) worldwide, and more than 350,000 die annually from liver disease caused by HCV
Egypt is confronted with an HCV disease burden of historical proportions that distinguishes this nation from others. It has the highest prevalence of hepatitis C virus (HCV) in the world, estimated nationally at 14.7% . Approximately, there are 10 million Egyptians carry the virus. Due to its chronic debilitating nature, it has tremendous social and financial impacts on our community. Hence, this trial aims to find a logic rational and effective treatment for Hepatitis C.
Extra-corporeal electro-magnetic irradiation: The wavelength of UV irradiation (UVI) lies in the range of 100-400 nm, and is further subdivided into UVA (315-400 nm), UVB (280-315 nm), and UVC (100-280 nm).UVC and UVB are directly absorbed by DNA bases causing serious DNA damages. On the other hand, DNA damage by UVA is indirect through the formation of Reactive Oxygen Species (ROS) that are formed when other cellular chromophores act as endogenous photo sensitizers. ROS can then react with and damage DNA, or interact with other cell structures such as membranes (lipids) and proteins. All of these different types of damage may hamper cell metabolic processes, such as protein synthesis and cell cycle progression, or induce mutations and cell death . Both Selenium itself and various selenoproteins are proposed to have antioxidant effects, reducing the biological impact of ROS on human cells .
Ultraviolet blood irradiation (UBI) was first used on humans in the early 1930s. The effectiveness of UBI in treating infections was studied extensively in the 1940s and it was found that UBI was extremely successful in treating such infections as peritonitis, pyelitis, sinusitis, puerperal sepsis and wound infections in all but the most advanced cases.Later studies showed UBI helped a number of patients with acute viral hepatitis .Recently, Energex Systems, a developer of advanced UBI technology, studied the effects of UBI therapy on viral loads in 13 patients with the infection and it showed some effect.
Optical and physical characteristics of electro-magnetic irradiation is the narrow band of ultraviolet A radiation with a peak at 365 nm with an average power about 18 µW/cm2 during the session.
For irradiation in the UVA region (315 nm- 400nm) the measured average irradiance was 0.12 mW/cm2in the place of circulating blood at any time of each session(40 sec).
The time integral of irradiance (prescribed exposure dose) is 0.144 J/cm2(1440 J/m2)for total radiant exposure time of 1200 sec (20 min) in all therapeutic sessions (up to maximum of 30 sessions in some particular cases).
The Irradiance power at all bands of output wavelength (250 nm - 1050 nm) from the optical lamps:
Wavelength (nm) Irradiance Power (mW/cm2) Ultraviolet Region A: UVA (315 nm -400 nm) 0.12 mW/cm2 Visible Band: VIS (400 nm - 700 nm) 110.8mW/cm2 Infrared Band: IR (700 nm - 1050 nm) 28.3mW/cm2
Selenium containing herbal food supplement:
No. Name Action
1. Ginseng Liver tonic
2. Saffron Anti - Oxidant
3. Dandelion Anti - Bacterial
4. Curcuma Anti - Parasitic
5. Vinca Rose Anti - Bacterial
6. Wormwood Anti - Oxidant
7. Lemon balm Anti - Bacterial
8. Papay Anti - viral
9. Achillia Anti - viral
10. Arctium Anti - viral
11. Aloe Anti - viral Anti - bacterial Anti - Fungal
12. Asfour Liver support
Detailed Description A Randomized, Open-Label, Study to investigate the Efficacy and Safety of extra-corporeal irradiation of circulating blood with and Selenium containing herbal food supplement tablets in the treatment of non-cirrhotic chronic hepatitis C subjects.
The null hypothesis: There is no difference in outcomes and cure rate of patients with Hepatitis C when using electromagnetic device or herbal tablets containing selenium are used with aim of treatment.
This study was submitted for ethical approval via the relevant Minister of health and Medical military sector Research Ethics Approval Committees.
Study Arm (s)
Interventions (arm 1):
Twenty four daily one hour sessions using Extra-corporeal electro-magnetic irradiation device combined with Herbal Food Supplement Selenium containing tables as an Anti Oxidant (Tablet A) starting 10 days before the radiation sessions and to continue for 24 weeks.
Intervention (arm 2):
Daily Herbal Food Supplement Selenium containing tablets for 24 weeks. What will happen to patients?
1. Invitation to participate:
Patients with hepatitis C virus infection will be identified from the attendee of the hepatology and tropical diseases clinics at our institute.
2. First Contact:
Each patient will then receive a phone call from the Research Nurse, to request an indication of whether they would like to participate in the study. If the patient would like to meet face-to-face, in which case arrangement would be made during the investigation tests or outpatient clinic appointments. Otherwise, questions will be answered over the telephone. This phone call is anticipated to last 10 minutes on average.
3. Initial Assessment Meeting and Informed Consent:
An initial meeting will then take place at which patients will be asked to give their informed consent.
In addition, demographics, past medical history and baseline observations will be noted. Up-to-date base line investigations will be performed including: FBC, renal functions, liver profile, Viral load PCR. The patients will then be informed of which group they have been randomized into (electromagnetic or herbal tablets). Patients in each group will have a detailed explanation of their corresponding management and booklet will be given to patients to take home.
4. The Electromagnetic Device group:
Those participants in the intervention group will be invited to attend the treatment cubicles to see the device. They will receive 20 minutes presentation about the theory of the device and how it functions.
5. Repeated Assessment Meetings:
* The Assessments performed in 3 above, will be repeated:
* On discharge (-24hrs to +48hrs) with additional returning to normal activities questions.
* 4-week out-patient appointment in research team clinic.
* 8-week out-patient appointment in research team clinic
* 12-week out-patient appointment in research team clinic.
* 24-week out-patient appointment in research team clinic.
6. Monitoring and Supportive Meetings:
• The research nurse will be available on the study mobile phone which will be supported by other members of the research team during periods of leave.
7. End of the study:
A final assessment meeting will take place six month after completion of treatment. Participants will be discharged back to the hepatology clinic for long term management. Research team will be notified of any long term adverse effects of either treatment arms.
Last follow up date: 48 weeks from baseline. Recruitment Status: Currently recruiting.
Supervision:
1. The Management and Monitoring Group (MMG). The study will be managed by a 'Management and Monitoring Group' (MMG) which will meet regularly, throughout the study, to manage it and to monitor progress. A Gantt chart showing the points at which MMG meetings are proposed is provided within the appendices. The study management will also comprise 5 sub-groups (involving specialized experts) who will interact with the MMG. A schematic showing all of these study management groups is given in the appendices of this document.
The MMG will comprise:
* Patient Representative.
* Professor Doctor: Tayseer Abdulaal, M.D., Internal medicine, Clinical Immunology Consultant, Egyptian Military Armed Forces
* Professor Doctor: Mostafa El-Awady, M.D.,Molecular Biology Consultant, Egyptian National Research Center
* Professor Doctor: Mostafa El-Nakib, M.D., Virology Consultant, Egyptian Military Armed Forces
* Professor Doctor: Hala Zayed, M.D., Internal medicine, Clinical Immunology Consultant, Egyptian Ministry of Health
* Professor Doctor: Ahmed El-Sawy, M.D., Gastroenterology Consultant, Egyptian Military Armed ForcesDr
2. The Patient Experience Sub-group The principal sub-group of the MMG will be one who will take responsibility for managing and monitoring the experiences of all patients during the study. This group will comprise Dr Tayseer Abdulaal and the Research Nurses and the Administrator. Therefore, it will be based within the hospital. This group will also be responsible for patient recruitment and for patient data entry onto an appropriate database. This group will make a significant contribution to the overall management of the study (which is done by the MMG) by raising awareness, within that group, of issues relating to all aspects of patient experience that arise as the study progresses.
3. The Critical side effects Sub-group A team of researchers, based at Egyptian military hospital, Ain Shams and Cairo University hospitals will meet within 24 hours of admission of any patients involved in the trial to any of the designated hospital. An action plan will include a thorough evaluation of the patient condition. Ife there is any concern regarding patient safety; the trial will be suspended for further assessment.
Background and Rationale: As many as 150 million persons are chronically infected with the hepatitis C virus (HCV) worldwide, and more than 350,000 die annually from liver disease caused by HCV
Egypt is confronted with an HCV disease burden of historical proportions that distinguishes this nation from others. It has the highest prevalence of hepatitis C virus (HCV) in the world, estimated nationally at 14.7% . Approximately, there are 10 million Egyptians carry the virus. Due to its chronic debilitating nature, it has tremendous social and financial impacts on our community. Hence, this trial aims to find a logic rational and effective treatment for Hepatitis C.
Extra-corporeal electro-magnetic irradiation: The wavelength of UV irradiation (UVI) lies in the range of 100-400 nm, and is further subdivided into UVA (315-400 nm), UVB (280-315 nm), and UVC (100-280 nm).UVC and UVB are directly absorbed by DNA bases causing serious DNA damages. On the other hand, DNA damage by UVA is indirect through the formation of Reactive Oxygen Species (ROS) that are formed when other cellular chromophores act as endogenous photo sensitizers. ROS can then react with and damage DNA, or interact with other cell structures such as membranes (lipids) and proteins. All of these different types of damage may hamper cell metabolic processes, such as protein synthesis and cell cycle progression, or induce mutations and cell death . Both Selenium itself and various selenoproteins are proposed to have antioxidant effects, reducing the biological impact of ROS on human cells .
Ultraviolet blood irradiation (UBI) was first used on humans in the early 1930s. The effectiveness of UBI in treating infections was studied extensively in the 1940s and it was found that UBI was extremely successful in treating such infections as peritonitis, pyelitis, sinusitis, puerperal sepsis and wound infections in all but the most advanced cases.Later studies showed UBI helped a number of patients with acute viral hepatitis .Recently, Energex Systems, a developer of advanced UBI technology, studied the effects of UBI therapy on viral loads in 13 patients with the infection and it showed some effect.
Optical and physical characteristics of electro-magnetic irradiation is the narrow band of ultraviolet A radiation with a peak at 365 nm with an average power about 18 µW/cm2 during the session.
For irradiation in the UVA region (315 nm- 400nm) the measured average irradiance was 0.12 mW/cm2in the place of circulating blood at any time of each session(40 sec).
The time integral of irradiance (prescribed exposure dose) is 0.144 J/cm2(1440 J/m2)for total radiant exposure time of 1200 sec (20 min) in all therapeutic sessions (up to maximum of 30 sessions in some particular cases).
The Irradiance power at all bands of output wavelength (250 nm - 1050 nm) from the optical lamps:
Wavelength (nm) Irradiance Power (mW/cm2) Ultraviolet Region A: UVA (315 nm -400 nm) 0.12 mW/cm2 Visible Band: VIS (400 nm - 700 nm) 110.8mW/cm2 Infrared Band: IR (700 nm - 1050 nm) 28.3mW/cm2
Selenium containing herbal food supplement:
No. Name Action
1. Ginseng Liver tonic
2. Saffron Anti - Oxidant
3. Dandelion Anti - Bacterial
4. Curcuma Anti - Parasitic
5. Vinca Rose Anti - Bacterial
6. Wormwood Anti - Oxidant
7. Lemon balm Anti - Bacterial
8. Papay Anti - viral
9. Achillia Anti - viral
10. Arctium Anti - viral
11. Aloe Anti - viral Anti - bacterial Anti - Fungal
12. Asfour Liver support
Detailed Description A Randomized, Open-Label, Study to investigate the Efficacy and Safety of extra-corporeal irradiation of circulating blood with and Selenium containing herbal food supplement tablets in the treatment of non-cirrhotic chronic hepatitis C subjects.
The null hypothesis: There is no difference in outcomes and cure rate of patients with Hepatitis C when using electromagnetic device or herbal tablets containing selenium are used with aim of treatment.
This study was submitted for ethical approval via the relevant Minister of health and Medical military sector Research Ethics Approval Committees.
Study Arm (s)
Interventions (arm 1):
Twenty four daily one hour sessions using Extra-corporeal electro-magnetic irradiation device combined with Herbal Food Supplement Selenium containing tables as an Anti Oxidant (Tablet A) starting 10 days before the radiation sessions and to continue for 24 weeks.
Intervention (arm 2):
Daily Herbal Food Supplement Selenium containing tablets for 24 weeks. What will happen to patients?
1. Invitation to participate:
Patients with hepatitis C virus infection will be identified from the attendee of the hepatology and tropical diseases clinics at our institute.
2. First Contact:
Each patient will then receive a phone call from the Research Nurse, to request an indication of whether they would like to participate in the study. If the patient would like to meet face-to-face, in which case arrangement would be made during the investigation tests or outpatient clinic appointments. Otherwise, questions will be answered over the telephone. This phone call is anticipated to last 10 minutes on average.
3. Initial Assessment Meeting and Informed Consent:
An initial meeting will then take place at which patients will be asked to give their informed consent.
In addition, demographics, past medical history and baseline observations will be noted. Up-to-date base line investigations will be performed including: FBC, renal functions, liver profile, Viral load PCR. The patients will then be informed of which group they have been randomized into (electromagnetic or herbal tablets). Patients in each group will have a detailed explanation of their corresponding management and booklet will be given to patients to take home.
4. The Electromagnetic Device group:
Those participants in the intervention group will be invited to attend the treatment cubicles to see the device. They will receive 20 minutes presentation about the theory of the device and how it functions.
5. Repeated Assessment Meetings:
* The Assessments performed in 3 above, will be repeated:
* On discharge (-24hrs to +48hrs) with additional returning to normal activities questions.
* 4-week out-patient appointment in research team clinic.
* 8-week out-patient appointment in research team clinic
* 12-week out-patient appointment in research team clinic.
* 24-week out-patient appointment in research team clinic.
6. Monitoring and Supportive Meetings:
• The research nurse will be available on the study mobile phone which will be supported by other members of the research team during periods of leave.
7. End of the study:
A final assessment meeting will take place six month after completion of treatment. Participants will be discharged back to the hepatology clinic for long term management. Research team will be notified of any long term adverse effects of either treatment arms.
Last follow up date: 48 weeks from baseline. Recruitment Status: Currently recruiting.
Supervision:
1. The Management and Monitoring Group (MMG). The study will be managed by a 'Management and Monitoring Group' (MMG) which will meet regularly, throughout the study, to manage it and to monitor progress. A Gantt chart showing the points at which MMG meetings are proposed is provided within the appendices. The study management will also comprise 5 sub-groups (involving specialized experts) who will interact with the MMG. A schematic showing all of these study management groups is given in the appendices of this document.
The MMG will comprise:
* Patient Representative.
* Professor Doctor: Tayseer Abdulaal, M.D., Internal medicine, Clinical Immunology Consultant, Egyptian Military Armed Forces
* Professor Doctor: Mostafa El-Awady, M.D.,Molecular Biology Consultant, Egyptian National Research Center
* Professor Doctor: Mostafa El-Nakib, M.D., Virology Consultant, Egyptian Military Armed Forces
* Professor Doctor: Hala Zayed, M.D., Internal medicine, Clinical Immunology Consultant, Egyptian Ministry of Health
* Professor Doctor: Ahmed El-Sawy, M.D., Gastroenterology Consultant, Egyptian Military Armed ForcesDr
2. The Patient Experience Sub-group The principal sub-group of the MMG will be one who will take responsibility for managing and monitoring the experiences of all patients during the study. This group will comprise Dr Tayseer Abdulaal and the Research Nurses and the Administrator. Therefore, it will be based within the hospital. This group will also be responsible for patient recruitment and for patient data entry onto an appropriate database. This group will make a significant contribution to the overall management of the study (which is done by the MMG) by raising awareness, within that group, of issues relating to all aspects of patient experience that arise as the study progresses.
3. The Critical side effects Sub-group A team of researchers, based at Egyptian military hospital, Ain Shams and Cairo University hospitals will meet within 24 hours of admission of any patients involved in the trial to any of the designated hospital. An action plan will include a thorough evaluation of the patient condition. Ife there is any concern regarding patient safety; the trial will be suspended for further assessment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hepatitis C
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Participants
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
UVA and Herbal
Twenty four daily one hour sessions using Extra-corporeal electro-magnetic irradiation device combined with Herbal Food Supplement Selenium containing tables as an Anti Oxidant (Tablet A) starting 10 days before the radiation sessions and to continue for 24 weeks
Group Type
EXPERIMENTAL
UVA
Intervention Type
DEVICE
device uses UVA
Herbal
Chronic HCV patients, non complicated will be treated by Herbal tablets only . 500 mg twice tablets every 6 hours daily for 6 months.
Group Type
EXPERIMENTAL
Herbal
Intervention Type
DIETARY_SUPPLEMENT
Herbal tablets, 1000 mg every 6 hours daily for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UVA
device uses UVA
Intervention Type
DEVICE
Herbal
Herbal tablets, 1000 mg every 6 hours daily for 6 months
Intervention Type
DIETARY_SUPPLEMENT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
UVA device
Herbal tablets
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female between the age of 21 and 60 years.
2. Female subjects of childbearing potential must be willing to use effective form of birth control.
3. Sexually active fertile females in childbearing period must have negative results for pregnancy tests.
4. Sexually active fertile males must agree either him or his wife to practicing effective form of birth control.
5. Subject should be treatment: Non cirrhotic HCV chronic Hepatitis.
6. Subjects must be able to understand and to adhere to the study visits schedule.
7. Body mass index (BMI) is \>18 to \<35kg/m2.
8. Must voluntarily sign and date an informed consent, approved by an Institutional Review Board/Ethics Committee (IRB/EC), prior to the initiation of any study-specific procedures.
9. Chronic HCV for at least 6 months prior to study enrolment. Chronic HCV infection is defined as one of the following:
* Positive for anti-HCV antibody or HCV RNA at least 6 months before Screening, and positive for HCV RNA and anti-HCV antibody at the time of Screening; OR
* Positive for anti-HCV antibody and HCV RNA at the time of Screening with a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed prior to enrolment with evidence of chronic hepatitis C disease).
10. Absence of cirrhosis judged by documented results of :-
* Liver Ultrasound. OR
* Fibro Test score of ≤ 0.75 and Aspartate Amino transferase to Platelet Ratio Index (APRI) ((AST/AST ULN)X100)/Plt in thousands) ≤ 2 at Screening, OR
* FibroScan® result of \<14.5kPa, OR
* The absence of cirrhosis based on a liver biopsy within the last 36months.
11. If the rewire multiple assessments on the same date for a subject, fibrosis score was calculated in the order of liver biopsy, FibroScan, and Fibro Test. If the rewire assessments on different dates for a subject by different methods, fibrosis score was calculated n the order of liver biopsy, FibroScan, and Fibro Test. If the rewire assessments on different dates for a subject by the same method, fibrosis score was calculated by maximum value.
12. Subject has a plasma HCV RNA level \>10,000 International Units (IU)/mLat screening.
2. Female subjects of childbearing potential must be willing to use effective form of birth control.
3. Sexually active fertile females in childbearing period must have negative results for pregnancy tests.
4. Sexually active fertile males must agree either him or his wife to practicing effective form of birth control.
5. Subject should be treatment: Non cirrhotic HCV chronic Hepatitis.
6. Subjects must be able to understand and to adhere to the study visits schedule.
7. Body mass index (BMI) is \>18 to \<35kg/m2.
8. Must voluntarily sign and date an informed consent, approved by an Institutional Review Board/Ethics Committee (IRB/EC), prior to the initiation of any study-specific procedures.
9. Chronic HCV for at least 6 months prior to study enrolment. Chronic HCV infection is defined as one of the following:
* Positive for anti-HCV antibody or HCV RNA at least 6 months before Screening, and positive for HCV RNA and anti-HCV antibody at the time of Screening; OR
* Positive for anti-HCV antibody and HCV RNA at the time of Screening with a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed prior to enrolment with evidence of chronic hepatitis C disease).
10. Absence of cirrhosis judged by documented results of :-
* Liver Ultrasound. OR
* Fibro Test score of ≤ 0.75 and Aspartate Amino transferase to Platelet Ratio Index (APRI) ((AST/AST ULN)X100)/Plt in thousands) ≤ 2 at Screening, OR
* FibroScan® result of \<14.5kPa, OR
* The absence of cirrhosis based on a liver biopsy within the last 36months.
11. If the rewire multiple assessments on the same date for a subject, fibrosis score was calculated in the order of liver biopsy, FibroScan, and Fibro Test. If the rewire assessments on different dates for a subject by different methods, fibrosis score was calculated n the order of liver biopsy, FibroScan, and Fibro Test. If the rewire assessments on different dates for a subject by the same method, fibrosis score was calculated by maximum value.
12. Subject has a plasma HCV RNA level \>10,000 International Units (IU)/mLat screening.
Exclusion Criteria
1. History of severe, life-threatening or other significant sensitivity to any drug.
2. Females who are pregnant or breast feeding.
3. Recent (within 6-months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol.
4. Positive test result for hepatitis B surface antigen (HbsAg) or anti-HIV antibodies (anti-HIV Ab).
5. Clinically significant abnormalities, other than HCV infection, based upon the results of a medical history, physical examination, vital signs, laboratory profile, a 12-lead electrocardiogram (ECG) and echocardiography that make the subject an unsuitable candidate for this study in the opinion of the Investigator.
6. History of uncontrolled seizures, cancer, or uncontrolled diabetes, as defined by a HbA1C level \>8.0%.
7. Any current or past clinical evidence of cirrhosis , a history or presence of ascites, oesophageal varices, or hepatic encephalopathy.
8. Known cause of liver disease other than chronic HCV infection.
9. Screening laboratory analyses show any of the following abnormal laboratory results:
* Alanine amino transferase (ALT) \>5X upper limit of normal (ULN),
* Aspartate amino transferase (AST) \>5X upper limit of normal (ULN),
* Calculated creatinine clearance (using Cockcroft-Gault method) \<50mL/min,
* Albumin\<lower limit of normal (LLN),
* Prothrombin time INR \> 1.5,
* Haemoglobin \< 11 %,
* Platelets\<120,000cellsper mm3
* Absolute neutrophil count \<1500cells/µL,
* Total bilirubin\> 1.5 mg/dL,
10. Clinically significant abnormal echocardiography or ECG.
11. Any contraindications to central venous catheter insertion.
12. Previous history of photosensitivity, skin cancer or presence of a positive family history of Skin Cancer.
2. Females who are pregnant or breast feeding.
3. Recent (within 6-months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol.
4. Positive test result for hepatitis B surface antigen (HbsAg) or anti-HIV antibodies (anti-HIV Ab).
5. Clinically significant abnormalities, other than HCV infection, based upon the results of a medical history, physical examination, vital signs, laboratory profile, a 12-lead electrocardiogram (ECG) and echocardiography that make the subject an unsuitable candidate for this study in the opinion of the Investigator.
6. History of uncontrolled seizures, cancer, or uncontrolled diabetes, as defined by a HbA1C level \>8.0%.
7. Any current or past clinical evidence of cirrhosis , a history or presence of ascites, oesophageal varices, or hepatic encephalopathy.
8. Known cause of liver disease other than chronic HCV infection.
9. Screening laboratory analyses show any of the following abnormal laboratory results:
* Alanine amino transferase (ALT) \>5X upper limit of normal (ULN),
* Aspartate amino transferase (AST) \>5X upper limit of normal (ULN),
* Calculated creatinine clearance (using Cockcroft-Gault method) \<50mL/min,
* Albumin\<lower limit of normal (LLN),
* Prothrombin time INR \> 1.5,
* Haemoglobin \< 11 %,
* Platelets\<120,000cellsper mm3
* Absolute neutrophil count \<1500cells/µL,
* Total bilirubin\> 1.5 mg/dL,
10. Clinically significant abnormal echocardiography or ECG.
11. Any contraindications to central venous catheter insertion.
12. Previous history of photosensitivity, skin cancer or presence of a positive family history of Skin Cancer.
Minimum Eligible Age
18 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EMS
INDUSTRY
Sponsor Role
collaborator
Egyptian Military Medical Services
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tayseer A Abdulaal, M.D.
Role: PRINCIPAL_INVESTIGATOR
EMMS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
EMMS
Cairo, Heliopolis, Egypt
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Egypt
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Lindsay KL. Introduction to therapy of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S114-20. doi: 10.1053/jhep.2002.36226.
Reference Type
BACKGROUND
Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759. No abstract available.
Reference Type
BACKGROUND
Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman SV, Fried MW, Rasenack J, Sarrazin C, Jensen DM, Lin A, Hoffman JH, Sedarati F. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol. 2003 Jul;39(1):106-11. doi: 10.1016/s0168-8278(03)00187-9.
Reference Type
BACKGROUND
Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, Castelnau C, Giuily N, El Ray A, Cardoso AC, Moucari R, Asselah T, Marcellin P. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010 Apr;51(4):1122-6. doi: 10.1002/hep.23444.
Reference Type
BACKGROUND
Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis. 2013 Jun 24;13:288. doi: 10.1186/1471-2334-13-288.
Reference Type
BACKGROUND
Moysan A, Marquis I, Gaboriau F, Santus R, Dubertret L, Morliere P. Ultraviolet A-induced lipid peroxidation and antioxidant defense systems in cultured human skin fibroblasts. J Invest Dermatol. 1993 May;100(5):692-8. doi: 10.1111/1523-1747.ep12472352.
Reference Type
BACKGROUND
Ridley AJ, Whiteside JR, McMillan TJ, Allinson SL. Cellular and sub-cellular responses to UVA in relation to carcinogenesis. Int J Radiat Biol. 2009 Mar;85(3):177-95. doi: 10.1080/09553000902740150.
Reference Type
BACKGROUND
Girard PM, Pozzebon M, Delacote F, Douki T, Smirnova V, Sage E. Inhibition of S-phase progression triggered by UVA-induced ROS does not require a functional DNA damage checkpoint response in mammalian cells. DNA Repair (Amst). 2008 Sep 1;7(9):1500-16. doi: 10.1016/j.dnarep.2008.05.004. Epub 2008 Jul 7.
Reference Type
BACKGROUND
Ferguson LR, Karunasinghe N, Zhu S, Wang AH. Selenium and its' role in the maintenance of genomic stability. Mutat Res. 2012 May 1;733(1-2):100-10. doi: 10.1016/j.mrfmmm.2011.12.011. Epub 2012 Jan 5.
Reference Type
BACKGROUND
MILEY G, CHRISTENSEN JA. Ultraviolet blood irradiation therapy; further studies in acute infections. Am J Surg. 1947 Apr;73(4):486-93. doi: 10.1016/0002-9610(47)90330-9. No abstract available.
Reference Type
BACKGROUND
Efficacy of ultraviolet blood irradiation therapy in the control of staphylococcemias. The American Journal of Surgery, Volume 64, Issue 3, June 1944, Pages 313-322
Reference Type
BACKGROUND
OLNEY RC. Treatment of viral hepatitis with the Knott technic of blood irradiation. Am J Surg. 1955 Sep;90(3):402-9. doi: 10.1016/0002-9610(55)90777-7. No abstract available.
Reference Type
BACKGROUND
George Miley Ultraviolet blood irradiation therapy (Knott technic) in acute pyogenic infections. The American Journal of Surgery, Volume 57, Issue 3, September 1942, Pages 493-50
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.hepatitiscentral.com/mt/archives/2007/08/light_therapy_a.html
New Technology and Methods to Fight Hepatitis C. Nicole Cutler L.Ac. August 6, 2007.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMMS 2014 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Screening, Treatment, and Eradication of Hep C
NCT05071261
NOT_YET_RECRUITING
Q-Trial in Patients With Hepatitis C
NCT01438320
COMPLETED
PHASE1
Acupuncture as an Adjunctive Treatment for Hepatitis C Patients
NCT01750515
UNKNOWN
NA
Counseling Hepatitis C Virus (HCV) Positive Patients for Cardiovascular Disease Risk Factors
NCT03402334
COMPLETED
NA
Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs
NCT03170076
UNKNOWN
Effect of Camel Milk on Chronic Hepatitis C
NCT02216045
COMPLETED
PHASE2
Evaluating Silymarin for Chronic Hepatitis C
NCT00030030
COMPLETED
PHASE2
Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection
NCT01572233
UNKNOWN
NA
Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C
NCT00643695
COMPLETED
NA
Hepatitis C-Video vs. Brochure Education Delivery
NCT04204447
COMPLETED
NA
Improving Quality of Life for Veterans Undergoing Interferon Treatment
NCT00117559
COMPLETED
NA
Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C
NCT02006823
COMPLETED
Treatment of Hepatitis c by Using Direct-acting Antiviral
NCT05372874
UNKNOWN
Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation
NCT00794911
COMPLETED
NA
Nutritional Support During Antiviral Therapy for Hepatitis C
NCT00841243
UNKNOWN
PHASE4
Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients
NCT04198584
COMPLETED
NA
Relinking Diagnosed But Untreated HCV Patients Back Into Care.
NCT05975216
COMPLETED
Acetyl-L-Carnitine Supplementation During HCV Therapy With Peg IFN-α2b Plus Ribavirin: Effect on Work Performance.
NCT01909557
COMPLETED
PHASE3
Way to Cure HCV Adherence
NCT02472925
COMPLETED
NA
Conquering Hepatitis C Via Micro-Elimination in Southwest Virginia
NCT03876470
UNKNOWN
Evaluating Treatment as Prevention Among People Who Inject Drugs in Dundee for HCV
NCT03356405
ACTIVE_NOT_RECRUITING
Boceprevir and Ucalm (St John&Apos;s Wort)
NCT01663922
COMPLETED
PHASE1
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
NCT02641158
COMPLETED
NA
the Possible Effect of the Antiviral Inhibitors for Treatment of Hepatitis C Virus Infection in Cardiac Function
NCT03166943
UNKNOWN
NA
Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients
NCT00871845
TERMINATED
NA